Why the study?
Does triple antiplatelet therapy (aspirin, clopidogrel, dipyridamole) reduce platelet and leucocyte function more than mono or dual therapy in healthy volunteers and stroke patients?
Population
22 subjects (11 healthy volunteers and 11 patients with previous ischaemic stroke)
Comparison
Triple antiplatelet therapy administered for two… vs Mono and dual antiplatelet therapies…
Design
RCT, randomised multiway crossover, measured ex vivo blinded to treatment
Follow-up
two weeks per treatment period
Authors
Loading...
Triple therapy adds no ex vivo benefit over aspirin-clopidogrel; challenges routine triple regimens in stroke pending clinical outcome trials.
Does triple antiplatelet therapy (aspirin, clopidogrel, dipyridamole) reduce platelet and leucocyte function more than mono or dual therapy in healthy volunteers and stroke patients?
Triple antiplatelet therapy (aspirin, clopidogrel, dipyridamole) does not provide additional ex vivo inhibition of platelet and leucocyte function compared to dual therapy with aspirin and clopidogrel.
Zhao et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: